Cadisegliatin (TTP399)
Type 1 Diabetes (adjunctive to insulin)
Phase 3Active (in Phase 3 trial)
Key Facts
Indication
Type 1 Diabetes (adjunctive to insulin)
Phase
Phase 3
Status
Active (in Phase 3 trial)
Company
About vTv Therapeutics
vTv Therapeutics is a clinical-stage company dedicated to improving the lives of people with diabetes through innovative oral therapies. Its primary mission is to develop cadisegliatin, which aims to become the first FDA-approved oral adjunctive treatment to insulin for Type 1 Diabetes, addressing the persistent challenge of hypoglycemia and glycemic control. The company is publicly traded on NASDAQ (VTVT) and is advancing its late-stage pipeline with a focus on liver-selective glucokinase activation. Its strategic direction is centered on successfully completing the Phase 3 trial and navigating the regulatory pathway for its lead candidate.
View full company profile